share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K：重大事件
美股sec公告 ·  06/24 08:05
Moomoo AI 已提取核心訊息
On June 20, 2024, bluebird bio, Inc., a biotechnology company listed on the Nasdaq Stock Market under the trading symbol BLUE, announced the appointment of Michael Cloonan to its board of directors. Cloonan was appointed as a Class I director and his term became effective on the same day. As part of his compensation, Cloonan will receive an annual retainer of $45,000, along with an initial award of a stock option to purchase 74,775 shares and 37,350 restricted stock units of the company's common stock. These equity awards will vest over a period of three years in annual installments. Additionally, Cloonan will be entering into the company's standard indemnification agreement for directors and officers. The company confirmed that Cloonan has no familial ties with any current director or executive officer and is not involved in any transaction with the company that would necessitate disclosure under SEC regulations. The appointment is part of the company's ongoing governance and leadership structure.
On June 20, 2024, bluebird bio, Inc., a biotechnology company listed on the Nasdaq Stock Market under the trading symbol BLUE, announced the appointment of Michael Cloonan to its board of directors. Cloonan was appointed as a Class I director and his term became effective on the same day. As part of his compensation, Cloonan will receive an annual retainer of $45,000, along with an initial award of a stock option to purchase 74,775 shares and 37,350 restricted stock units of the company's common stock. These equity awards will vest over a period of three years in annual installments. Additionally, Cloonan will be entering into the company's standard indemnification agreement for directors and officers. The company confirmed that Cloonan has no familial ties with any current director or executive officer and is not involved in any transaction with the company that would necessitate disclosure under SEC regulations. The appointment is part of the company's ongoing governance and leadership structure.
2024年6月20日，生物技術公司bluebird bio, Inc.[納斯達克上市代碼BLUE]宣佈任命邁克爾·克魯南(Michael Cloonan)爲其董事會I類董事，任期自同日起生效。作爲他的薪酬組成部分，克魯南將獲得45000美元的年度報酬，以及74,775股可購買公司普通股的股票期權和37,350股受限制的公司普通股。這些權益獎勵將在三年內分別以年度分期支付。此外，克魯南將參加公司的標準董事和高管賠款協議。該公司確認，克魯南與任何現任董事或執行官不具有家庭關係，也沒有與公司進行任何需要根據證券交易委員會監管披露的交易。該任命是公司不斷完善其治理和領導架構的一部分。
2024年6月20日，生物技術公司bluebird bio, Inc.[納斯達克上市代碼BLUE]宣佈任命邁克爾·克魯南(Michael Cloonan)爲其董事會I類董事，任期自同日起生效。作爲他的薪酬組成部分，克魯南將獲得45000美元的年度報酬，以及74,775股可購買公司普通股的股票期權和37,350股受限制的公司普通股。這些權益獎勵將在三年內分別以年度分期支付。此外，克魯南將參加公司的標準董事和高管賠款協議。該公司確認，克魯南與任何現任董事或執行官不具有家庭關係，也沒有與公司進行任何需要根據證券交易委員會監管披露的交易。該任命是公司不斷完善其治理和領導架構的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息